IL32 and neoplasm: However, treatment with AAV2-Nk4 prior to immune therapy, eliminated the anti-tumour effects of AAV2-GB treatment (Figure 4e), with tumour growth in this group similar to controls (p vs. untreated p = 0.52, p vs. null vector control p = 0.38).